Upgrade to SI Premium - Free Trial

Corvus Pharmaceuticals (CRVS) PT Lowered to $7 at Oppenheimer

March 20, 2024 4:38 AM
Oppenheimer analyst Jeff Jones lowered the price target on Corvus Pharmaceuticals (NASDAQ: CRVS) to $7.00 (from $8.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change

Next Articles